269 related articles for article (PubMed ID: 25461393)
1. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
2. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Gangoiti MV; Cortizo AM; Arnol V; Felice JI; McCarthy AD
Eur J Pharmacol; 2008 Dec; 600(1-3):140-7. PubMed ID: 18973752
[TBL] [Abstract][Full Text] [Related]
3. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.
Corrado A; Neve A; Maruotti N; Gaudio A; Marucci A; Cantatore FP
Clin Exp Rheumatol; 2010; 28(6):873-9. PubMed ID: 21205463
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment.
Hu L; Han J; Yang X; Wang Y; Pan H; Xu L
Mol Med Rep; 2016 Oct; 14(4):3535-42. PubMed ID: 27573706
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.
Ribeiro V; Garcia M; Oliveira R; Gomes PS; Colaço B; Fernandes MH
J Cell Mol Med; 2014 Jan; 18(1):27-37. PubMed ID: 24373581
[TBL] [Abstract][Full Text] [Related]
7. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
Manzano-Moreno FJ; Ramos-Torrecillas J; Melguizo-Rodríguez L; Illescas-Montes R; Ruiz C; García-Martínez O
Int J Med Sci; 2018; 15(4):359-367. PubMed ID: 29511371
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway.
Tsai SH; Huang PH; Peng YJ; Chang WC; Tsai HY; Leu HB; Chen JW; Lin SJ
Cardiovasc Res; 2013 Dec; 100(3):501-10. PubMed ID: 24225494
[TBL] [Abstract][Full Text] [Related]
11. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
12. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
13. Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.
Lindtner RA; Tiaden AN; Genelin K; Ebner HL; Manzl C; Klawitter M; Sitte I; von Rechenberg B; Blauth M; Richards PJ
Osteoporos Int; 2014 Mar; 25(3):1151-61. PubMed ID: 23974861
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A.
Deckers MM; van Bezooijen RL; van der Horst G; Hoogendam J; van Der Bent C; Papapoulos SE; Löwik CW
Endocrinology; 2002 Apr; 143(4):1545-53. PubMed ID: 11897714
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.
Ohe JY; Kwon YD; Lee HW
Clin Oral Investig; 2012 Aug; 16(4):1153-9. PubMed ID: 21938481
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment.
Neve A; Cantatore FP; Corrado A; Gaudio A; Ruggieri S; Ribatti D
Regul Pept; 2013 Jun; 184():81-4. PubMed ID: 23500833
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of osteoblast function in vitro by aminobisphosphonates.
Orriss IR; Key ML; Colston KW; Arnett TR
J Cell Biochem; 2009 Jan; 106(1):109-18. PubMed ID: 19003973
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Açil Y; Arndt ML; Gülses A; Wieker H; Naujokat H; Ayna M; Wiltfang J
J Craniomaxillofac Surg; 2018 Apr; 46(4):538-546. PubMed ID: 29454604
[TBL] [Abstract][Full Text] [Related]
20. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
